As per the deal, NewVac gains exclusive rights to develop and commercialize Janssen’s quisinostat in Russia and other Eastern European countries.
NewVac board chairman Nikolay Savchuk said the company was in search of a next generation HDAC compound with the potential to demonstrate clinical activity in solid tumors besides potential for clinically meaningful improvement of outcomes in resistant or refractory disease.
"NewVac will initiate solid tumor combination therapy studies which are accompanied by translational efforts," Savchuk added.
Janssen will contribute its knowledge in external global clinical trials to the development program.
The experimental drug candidate Quisinostat is a generation histone deacetylase inhibitor with antineoplastic activity.